Plain-English translation of NCT07504796 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial tests whether using a blood test to detect cancer DNA can help doctors make smarter treatment decisions for advanced melanoma patients taking and . Instead of waiting for imaging scans to show that cancer is growing back, this study uses as an additional medication when the blood test shows signs of disease recurrence. The goal is to catch treatment failure earlier and avoid unnecessary medications for patients who are doing well.
Currently, doctors rely on imaging scans to decide when to switch melanoma treatments, but by then the cancer may have already started growing. This study aims to use an earlier warning signal—detectable cancer DNA in the blood—to help doctors add or switch treatments sooner, potentially improving outcomes while also sparing patients from unnecessary side effects and costs.
You likely qualify if…
You likely don't qualify if…
You will receive and intravenously every 4 weeks as your standard treatment. At week 6, doctors will check a blood test for cancer DNA; based on these results, you may either continue the same treatment, or be randomly assigned to add or switch your regimen. You'll have regular imaging scans and blood tests to monitor your response, with follow-up visits continuing for up to 2 years or until your cancer progresses.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States